Test Results Indicate that Molekule’s Air Pro Purifier Reduces Hospital Length of Stay by Approximately Two Days in COVID-19 Patients
27 Junio 2023 - 6:00AM
Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq:
MKUL) today announced the results of a research study evaluating
the effect of in-room air purification on the clinical recovery in
mild and moderate COVID-19 patients. The study, conducted at two
Mercyhealth hospitals, indicates a statistically significant
outcome, with length of stay reduced by approximately two (2) days
when Molekule’s Air Pro purifier with its patented PECO filter is
running in the patient room.
“We know our devices are proven to effectively
destroy many dangerous pathogens from the air. These latest results
underscore the integral role improved indoor air quality (“IAQ”)
can have in recovery from illness as well,” said Jason DiBona,
Chief Executive Officer of Molekule. “We are dedicated to
revolutionizing IAQ and are thrilled this study validates the
immense potential to enhance patient care through our innovative
solutions. These positive findings further solidify our commitment
to safe air for everyone and the importance it has on our health
and wellbeing.
“The results from the adequately powered blinded
randomized controlled trial comparing Molekule’s Air Pro purifier
versus placebo shows that, on average, use of Molekule’s Air Pro
purifier was associated with a two day shorter stay in the hospital
for COVID-19 patients - the primary outcome of the trial. This
finding is not only statistically significant but also clinically
meaningful considering the shorter stay and its impact on overall
savings for the patients and the healthcare system and demonstrates
the significance of clean air in healthcare settings,” said Dr.
Ambuj Kumar, University of South Florida, Study Collaborator. “The
shortened recovery process was clear in those with access to
improved air quality, offering new ways that we can better support
patients utilizing all the tools at our disposal. As technology
improves, we see the imperative role it can play in improving both
patient care as well as better managing hospital resources.”
Key Details from the Study
- The placebo-controlled trial was
conducted for one year (January 2022 to December 2022) at two
Mercyhealth hospital locations in Wisconsin and Illinois.
- The results showed a significant
difference in the length of stay with the use of the Air Pro device
with a patented PECO filter compared with no filter (placebo).
- On average,
patients with Air Pro devices with filter use stayed two days less
in the hospital compared with placebo devices.
Molekule has the largest range of proprietary
and patented FDA-cleared air purification devices, which have been
proven to destroy SARS-CoV-2, H1N1 flu virus, VOCs, allergens, mold
and many other airborne pollutants. Molekule’s patented photo
electrochemical oxidation (PECO) technology, with FDA clearance for
medical use, is one-of-a-kind in its capability to not only
capture, but break down pollutants like bacteria, viruses, mold,
allergens & more. Molekule devices are the only air purifiers
to use patented PECO technology to destroy pollutants. The devices
are part of a state-of-the-art advanced solutions platform, which
includes IAQ monitoring and internet-of-things (“IoT”) device
control. Molekule technology can measure the temperature, humidity,
CO, VOCs, PM-1, PM-2.5, PM-10, ozone and indoor CO2 concentrations
anywhere deployed in buildings and other indoor spaces.
If you are interested in a quote for your
organization, please inquire at: https://molekule.com/business.
About Molekule
Molekule (Nasdaq: MKUL) is creating safer,
healthier indoor environments worldwide, starting with our most
essential resource: the air we breathe. Based on over 25 years of
research and development, the company creates scientifically proven
technology to improve indoor air quality for individuals,
businesses, schools, hospitals, and organizations of all sizes.
Molekule's lineup of air purification solutions incorporates
medical grade HEPA and their patented photo electrochemical
oxidation (PECO) technology, which surpasses traditional filters by
effectively destroying a wide range of pollutants including VOCs,
mold, bacteria, viruses, and allergens. These devices have
undergone rigorous assessments and validations by third-party
laboratories, earning FDA clearance as medical devices. It’s all
part of Molekule’s vision of changing the world from the indoors
out. For more details, please visit https://molekule.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based upon current beliefs and
expectations of our management and are subject to known and unknown
risks and uncertainties. Words or expressions such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “estimates,” “may,”
“will,” “projects,” “could,” “should,” “would,” “seek,” “forecast,”
or other similar expressions help identify forward-looking
statements. Factors that could cause actual events to differ
include, but are not limited to:
- general economic conditions in the
markets where we operate;
- the impact of the COVID-19 pandemic
and related prophylactic measures;
- expected timing of regulatory
approvals and product launches;
- non-performance of third-party
vendors and contractors;
- risks related to our ability to
successfully sell our products and the market reception to and
performance of our products;
- the possibility that our products
do not ultimately perform in line with our testing or that prior
test results may not be replicated in future studies;
- our compliance with, and changes
to, applicable laws and regulations;
- our limited operating history;
- our ability to manage growth;
- our ability to obtain additional
financing when and if needed;
- our ability to expand product
offerings;
- our ability to compete with others
in our industry;
- our ability to protect our
intellectual property;
- the ability of certain stockholders
to determine the outcome of matters that require stockholder
approval;
- our ability to retain the listing
of our common stock on Nasdaq;
- our ability to defend against legal
proceedings;
- success in retaining or recruiting,
or changes required in, our officers, key employees or
directors;
- the risk that the merger between
Molekule and Aura may not be completed; and
- other economic,
business, competitive, and regulatory factors affecting the
businesses of the Company generally, including but not limited to
those set forth in Molekule’s filings with the SEC, including in
the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of
Molekule’s latest annual report on Form 10-K, as amended, and other
SEC filings.
Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and actual
results may differ materially from those in the forward-looking
statements as a result of various factors. Although we believe that
the expectations reflected in the forward-looking statements are
reasonable based on information currently available, we cannot
assure you that the expectations will prove to have been correct.
Accordingly, you should not place undue reliance on these
forward-looking statements. In any event, these statements speak
only as of the date of this release. We assume no obligation to
revise or update any of the forward-looking statements to reflect
events or circumstances after the date of this release or to
reflect new information or the occurrence of unanticipated
events.
Media Contact Press@molekule.com
Investor Relations Contacts Ryan TylerChief
Financial Officer, Molekule Ryan.Tyler@molekule.com
MATTIO Communications molekule@mattio.com
Molekule (NASDAQ:MKUL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Molekule (NASDAQ:MKUL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024